The Efficacy and Safety of Tirofiban Enhanced Antiplatelet Therapy in the Treatment of Ruptured Intracranial Aneurysms With Stent

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 622 participants.

Also called NCT07818083

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 622 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07818083
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07818083. Randomized; triple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2028-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of Tirofiban Enhanced Antiplatelet Therapy in the Treatment of Ruptured Intracranial Aneurysms With Stent
Acronym
TEARIAS
Condition
Ruptured Intracranial Aneurysms
Condition
Subarachnoid Hemorrhage, Aneurysmal
Intervention (Drug)
Tirofiban+Oral Dual Antiplatelet Therapy
Intervention (Drug)
Dual Antiplatelet Therapy plus Normal Saline
Lead sponsor
First Affiliated Hospital of Fujian Medical University (class: other)

Record details

Record id
cardio:ct-nct07818083
Content hash
76cfe03d82f87f2629f80afff125dfd66eab1b4de0fbee31524bae4a42aa5dea